Last month we asked for your feedback about the FDA’s decision to refuse to file Biohaven’s NDA for troriluzole. More than 3,000 people stepped up to make their voices heard!
97% of respondents agree that the FDA should apply regulatory flexibility and accept the NDA filing for troriluzole for a full review.
We are happy to announce that the feedback you provided was delivered to the FDA last week. The Community Response packet includes information about SCA3, a formal letter from NAF, a full summary of the survey results, a letter from NAF’s Medical and Research Advisory Board, and more than 1,200 comments from community members.
Thank you to all who took the time to provide your input! We will keep you updated when we hear more about next steps for troriluzole.
Read Our Latest Blogs
Community Response Regarding Troriluzole Delivered to FDA
NAF Team Member Joins Climbing Kili for a Cure
Unraveling Ancestry: Mary Hogan’s Journey
Tell Us Why You Think Ataxia Deserves Regulatory Flexibility
NAF Calls on the FDA to Apply Regulatory Flexibility and Accept the NDA Filing for troriluzole
Advocating for Ataxia: My Virtual Experience on Hill Day
